Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VDMN-21 Patch Low Dose · 1 trial · 3 indications
Complete clinical resolution is defined as the target lesion with area = 0.
| Arm | Type | Description |
|---|---|---|
| Treatment Group A (Low Dose) | EXPERIMENTAL | Low does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Treatment Group B (High Dose) | EXPERIMENTAL | High does patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Treatment Group C (Vehicle) | PLACEBO_COMPARATOR | Vehicle patch will be applied adjacent to the target wart and remain in place for 5 minutes then removed. There may be up to 6 treatments (approximately 1 per month). |
| Name | Type | Description |
|---|---|---|
| VDMN-21 Patch Low Dose | DRUG | Microneedle patch containing 125 mcg of active drug |
| VDMN-21 Patch High Dose | DRUG | Microneedle patch containing 250 mcg of active drug |
| Vehicle Patch | DRUG | Placebo microneedle patch containing no active drug (i.e., placebo) |
Inclusion Criteria: * Subject is a male or non-pregnant female, 9 to 65 years of age. * Subject has provided written informed consent/assent. * Females must be post-menopausal, surgically sterile, or use an effective method of birth control. Women of childbearing potential (WOCBP) must have a negat...
VDMN-21 Patch Low Dose is an investigational small molecule patch being developed for the treatment of Verruca Vulgaris, commonly known as common warts. It is designed for topical application to treat this infectious disease condition. The drug is currently in clinical development and has not been approved by regulatory authorities.
The specific molecular target of VDMN-21 Patch Low Dose has not been disclosed in available information. The drug is classified as a small molecule modality and is being investigated for its safety and efficacy in treating Verruca Vulgaris, or common warts, through topical application as a patch.
VDMN-21 Patch Low Dose is being developed by Veradermics, Incorporated, a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational patch for the treatment of common warts.
VDMN-21 Patch Low Dose is in Phase 2 clinical development. It is an investigational drug that has not been approved by the FDA or any other regulatory agency. The drug is being studied for its safety and efficacy in treating Verruca Vulgaris, or common warts.
VDMN-21 Patch Low Dose has been studied in one completed Phase 2 clinical trial, identified as NCT05799157. This randomized, double-blind, placebo-controlled trial enrolled 153 participants in the United States to evaluate the safety and efficacy of the patch in subjects with common warts.
VDMN-21 Patch Low Dose is a specific formulation of the investigational drug VDMN-21, developed by Veradermics, Incorporated. The 'Low Dose' designation indicates a particular strength of the patch being evaluated in clinical trials for the treatment of common warts.